REFERENCES:
Al-Tawfiq, J. A., Al-Homoud, A. H., & Memish, Z. A. (2020). Remdesivir as a possible therapeutic option for the COVID-19. Travel medicine and infectious disease, 34 , 101615.https:// doi:10.1016/j.tmaid.2020.101615.
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J. . . . & Liu, L. (2020). Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing) , 10.1016/j.eng.2020.1003.1007.https:// doi:10.1016/j.eng.2020.03.007.
Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N. . . . & Dagna, L. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European journal of internal medicine, 76 , 43-49.https:// doi:10.1016/j.ejim.2020.05.021.
Cantore, I., & Valente, P. (2020). Convalescent plasma from COVID 19 patients enhances intensive care unit survival rate. A preliminary report. Transfusion and Apheresis Science, https://doi.org/10.1016/j.transci.2020.102848 .https://.
Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis.Journal of medical virology, 92 (4), 418-423.https:// doi:10.1002/jmv.25681.
Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020). The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.Cytokine & growth factor reviews .https:// doi:10.1016/j.cytogfr.2020.05.003.
Devaux, C. A., Rolain, J. M., Colson, P., & Raoult, D. (2020). New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?International journal of antimicrobial agents, 55 (5), 105938.https:// doi:10.1016/j.ijantimicag.2020.105938.
Duan, K., Liu, B., Li, C., Zhang, H., Yu, T., Qu, J. . . . & Hu, Y. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences, 117 (17), 9490-9496.https://.
Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M. . . . & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents , 105949.https:// doi:10.1016/j.ijantimicag.2020.105949.
Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A. . . . & Lescure, F.-X. (2020). Compassionate use of remdesivir for patients with severe Covid-19.New England Journal of Medicine, 382 (24), 2327-2336.https://.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S. . . . & Pöhlmann, S. (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181 (2), 271-280.e278.https:// doi:10.1016/j.cell.2020.02.052.
June, R. R., & Olsen, N. J. (2016). Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert opinion on biological therapy, 16 (10), 1303-1309.https:// doi:10.1080/14712598.2016.1217988.
Kalil, A. C. (2020). Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. Jama .https:// doi:10.1001/jama.2020.4742.
Kumar, S., Zhi, K., Mukherji, A., & Gerth, K. (2020). Repurposing antiviral protease inhibitors using extracellular vesicles for potential therapy of COVID-19. Viruses , 12 (5), 486.‏
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020). Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet (London, England), 395 (10223), 473-475.https://.
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. Jama, 323 (18), 1824-1836.https:// doi:10.1001/jama.2020.6019.
Sanofi. (2020). Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19. Retrieved from http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19
Sheahan, T. P., Sims, A. C., Leist, S. R., Schäfer, A., Won, J., Brown, A. J. . . . & Baric, R. S. (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature communications, 11 (1), 222.https:// doi:10.1038/s41467-019-13940-6.
Sallard, E., Lescure, F. X., Yazdanpanah, Y., Mentre, F., Peiffer-Smadja, N., Florence, A. D. E. R., … & BOUADMA, L. (2020). Type 1 interferons as a potential treatment against COVID-19.Antiviral Research , 104791.‏
Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F. . . . & Deng, B. (2020). The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study. Medrxiv .https:// doi:10.1101/2020.03.28.20046144.
Tang , N., Bai , H., Chen, X., Gong , J., Li , D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis , doi:10.1111/jth.14817.https://.
Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M. . . . & Hu, Z. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. 30 (3), 269-271.https:// doi:10.1038/s41422-020-0282-0.
Xu, K., Yanfei, C., Yuan, J., Yi, P., Ding, C., Wu, W. . . . & Zhao, H. (2020). Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study. Journal of medical virology , http://dx.doi.org/10.2139/ssrn.3542148.https://.
Yao, T.-T., Qian, J.-D., Zhu, W.-Y., Wang, Y., & Wang, G.-Q. (2020). A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. Journal of medical virology, 92 (6), 556-563.https:// doi:10.1002/jmv.25729.
Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020a). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive care medicine, 46 (4), 586-590.https:// doi:10.1007/s00134-020-05985-9.
Zhang, C., Wu, Z., Li, J. W., Zhao, H., & Wang, G. Q. (2020b). Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. International journal of antimicrobial agents, 55 (5), 105954.https:// doi:10.1016/j.ijantimicag.2020.105954.
Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., Pan, T., & Zhang, H. (2020c). Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv , 2020.2002.2005.935387.https:// doi:10.1101/2020.02.05.935387.
Zhang, R., Wang, X., Ni, L., Di, X., Ma, B., Niu, S. . . . & Reiter, R. J. (2020d). COVID-19: Melatonin as a potential adjuvant treatment. Life sciences, 250 , 117583.https:// doi:10.1016/j.lfs.2020.117583.